SGMO
Sangamo Therapeutics Inc

14,348
Mkt Cap
$139.68M
Volume
6.92M
52W High
$2.84
52W Low
$0.3846
PE Ratio
-0.94
SGMO Fundamentals
Price
$0.4641
Prev Close
$0.4151
Open
$0.426
50D MA
$0.5784
Beta
1.68
Avg. Volume
4.49M
EPS (Annual)
-$0.4856
P/B
21.41
Rev/Employee
$315,846.99
Loading...
Loading...
News
all
press releases
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Hold" from Brokerages
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has been given a consensus recommendation of "Hold" by the seven ratings firms that are presently covering the firm, MarketBeat Ratings...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Sangamo Therapeutics (NASDAQ:SGMO) Downgraded to Strong Sell Rating by Wall Street Zen
Wall Street Zen cut shares of Sangamo Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Saturday...
MarketBeat·11d ago
News Placeholder
Research Analysts Offer Predictions for SGMO FY2025 Earnings
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright decreased their FY2025 earnings per share estimates for Sangamo Therapeutics in a report released on Monday, November 10th. HC...
MarketBeat·13d ago
News Placeholder
Q4 Earnings Forecast for SGMO Issued By HC Wainwright
Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright issued their Q4 2025 earnings estimates for shares of Sangamo Therapeutics in a note issued to investors on Monday, November...
MarketBeat·14d ago
News Placeholder
Sangamo Therapeutics (NASDAQ:SGMO) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS
Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus...
MarketBeat·19d ago
News Placeholder
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of -266.67% and -98.84%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
What Makes Sangamo (SGMO) a New Buy Stock
Sangamo (SGMO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3mo ago
News Placeholder
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates
Sangamo (SGMO) delivered earnings and revenue surprises of -14.29% and -9.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of -35.29% and -4.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Zacks·7mo ago

Latest SGMO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.